
|Articles|August 1, 2007
- Volume 0 0
ADVISORY COMMITTEE WILL ADDRESS RISK COMMUNICATION
Advertisement
The FDA will form a new advisory committee of outside specialists to advise the agency on how to inform the public about the risks and benefits of medicines and medical devices. The Risk Communication Advisory Committee will:
- Help the FDA better understand the communication needs and priorities of the general public
- Advise the FDA on the development of strategic plans to communicate product risks and benefits
- Make recommendations to the FDA based on current research about crafting risk and benefit messages, as well as how to effectively communicate specific product information to vulnerable audiences
The committee "will bring together a broad range of experts and views to help improve the FDA's communication of the science-based information about product risks and benefits that the public needs to make informed decisions."
Articles in this issue
almost 19 years ago
The Facts of Licealmost 19 years ago
compounding HOTLINEalmost 19 years ago
can you READ these Rxs?almost 19 years ago
can you READ these Rxs?almost 19 years ago
WARFARIN-RELATED COMPLICATIONS INCREASE WITH AGEalmost 19 years ago
IS NATTOKINASE A NATURAL ALTERNATIVE TO WARFARIN?almost 19 years ago
HIGH RATES OF WARFARIN-RELATED AEs IN NURSING HOMESalmost 19 years ago
LONG-TERM ASPIRIN USE MAY REDUCE RISK OF SOME CANCERSalmost 19 years ago
Embracing and Advocating Change in the Pharmacy Professionalmost 19 years ago
Improving Pharmaceutical Care of the Elderly Patient with GERDAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
3
Why Some Patients Do Not Respond to GLP-1 Therapies
4
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
5








































































































































